The federal decision to move state-licensed medical cannabis from Schedule I to Schedule III of the Controlled Substances Act (CSA), signed by Acting Attorney General Todd Blanche, is prompting a re-evaluation of policy and market dynamics across the United States. This significant federal action, which also reclassified FDA-approved marijuana products, creates a DEA registration pathway for state-licensed operators and prospectively eliminates the Section 280E tax disallowance for these businesses, as reported by National Law Review. While the federal government’s move does not legally compel states to alter their existing cannabis laws, it introduces a new political and economic calculus for state legislatures and the industry, building on earlier coverage of federal reclassification.
Federal Action, State Autonomy, and Political Tailwinds
The rescheduling order is a federal action with federal effects, meaning it does not mandate any state to establish a medical cannabis program, expand an existing one, or increase patient access. States retain their legislative prerogatives and can continue their current policies. However, the federal acknowledgment that medical cannabis has accepted medical use under federal law provides a political tailwind for expansion efforts, particularly in states with Republican-controlled legislatures and governors.
A YouGov/Economist poll from April 2026 indicated 84% of Americans, including 81% of Republicans, support medical cannabis legalization. The primary obstacle to expansion in conservative states has often been the political risk for legislators associated with endorsing a substance federally illegal. Acting Attorney General Blanche framed the order as “delivering on President Trump’s promise to expand Americans’ access to medical treatment options.” This framing offers Republican state legislators a new argument: that voting for medical cannabis programs is now consistent with, rather than in defiance of, federal policy under a Republican administration, as detailed by National Law Review.
Impact on States with Existing Programs
The effects of federal medical cannabis rescheduling are likely to be most pronounced in states with existing medical programs where access has been limited by factors such as low THC caps, narrow qualifying condition lists, or insufficient infrastructure. Georgia serves as a recent example, with Governor Brian Kemp signing SB 220, the “Putting Georgia’s Patients First Act,” on May 12, 2026. This bill removed the previous 5% THC potency cap, replaced it with a 12,000-milligram possession limit, added new qualifying conditions, and allowed vaporization for patients over 21. While the bill had legislative momentum, the timing suggests the rescheduling order provided political cover for Republican legislators.
Other states with restrictive programs, such as Texas (extremely low-THC products, limited conditions), Iowa (4.5 grams of THC per 90 days cap), and Tennessee (CBD-only framework), may experience similar dynamics. Advocates in these states can now argue that the federal government has confirmed the medical value of the plant, potentially reducing the political cost of expansion.
Challenges in States Without Comprehensive Programs
As of the rescheduling order’s effective date, approximately nine states lacked comprehensive medical cannabis programs. These include Idaho, Indiana, Kansas, North Carolina, South Carolina, Tennessee, Wisconsin, and Wyoming. While the rescheduling offers some marginal assistance, these states often have structural reasons for their resistance.
- North Carolina: A comprehensive medical cannabis bill, HB 1011 (the Compassionate Care Act), is active in the current legislature, which began its 2026 session on April 21. The federal backdrop and competitive pressure from neighboring states like Virginia and Georgia may accelerate action.
- South Carolina: A conservative medical cannabis bill (S 0053) faces cultural conservatism as its primary obstacle. The Trump administration’s endorsement diminishes the federal law tension argument previously used for caution.
- Wisconsin: A medical cannabis bill passed the Senate Health Committee in February 2026 but did not receive a floor vote. Republican Governor Tony Evers supports medical cannabis, but legislative leadership remains a bottleneck.
- Idaho: This state presents a unique situation, with legislators referring a constitutional amendment (HJR 4) to the November 2026 ballot that would strip voters of the ability to legalize prohibited drugs via citizen initiative. This move could significantly reduce pathways to access, despite medical cannabis initiative proponents gathering signatures for a separate November 2026 ballot measure.
Kansas, Indiana, and Wyoming are considered the least likely for near-term progress, with legislative resistance remaining strong despite the improved federal environment.
Economic Shifts in Dual-Program States
In states with both medical and adult-use cannabis programs, the medical cannabis rescheduling could lead to a reallocation of demand. State-licensed medical cannabis is now a Schedule III substance under federal law, a distinction not extended to adult-use cannabis. This could make medical programs more attractive to consumers due to several factors:
- Health Insurance/HSA/FSA: It becomes theoretically possible for health insurers, health savings accounts, or flexible spending accounts to treat physician-recommended medical cannabis as a reimbursable medical expense.
- Taxes: Many dual-program states impose lower sales tax rates on medical cannabis than on adult-use products. For example, Illinois’s adult-use tax can reach 34% or higher, while medical cannabis is taxed at a significantly lower rate.
- Product Access: Medical dispensaries in many states are authorized to carry higher-potency products or larger purchase quantities.
Furthermore, the elimination of Section 280E for medical cannabis operators could allow them to pass savings to consumers, further tilting the playing field towards medical programs, according to National Law Review.
Ongoing Regulatory Scrutiny and Broader Federal Impacts
Following the reclassification, the Drug Enforcement Administration (DEA) is set to hold a hearing starting June 29 on the issue of more comprehensively moving marijuana to Schedule III. Advocacy organizations on both sides of the debate have filed notices of intent to participate, as reported by Marijuana Moment.
- The National Organization for the Reform of Marijuana Laws (NORML) has filed to participate, arguing that while Schedule III is an interim correction, cannabis should ultimately be removed from the CSA entirely, or descheduled. NORML emphasizes the need to represent adult cannabis consumers.
- The prohibitionist organization Smart Approaches to Marijuana (SAM) also intends to participate, stating that rescheduling to Schedule III lacks scientific basis and would benefit the industry at the expense of public health.
Beyond the DEA hearing, the medical cannabis rescheduling is already having broader federal impacts. The Congressional Research Service has issued a report noting that certified patients possessing medical cannabis from state-licensed dispensaries now have certain protections under Schedule III. The Bureau of Alcohol, Tobacco, Firearms and Explosives (ATF) has drafted an update to its gun purchase form, acknowledging the federally legal status of medical cannabis under rescheduling by only prohibiting recreational use. The U.S. Department of the Treasury and Internal Revenue Service (IRS) plan to issue new tax guidance for the industry, allowing state-licensed medical cannabis businesses to take federal tax deductions previously barred by IRS code 280E. However, the Department of Transportation has clarified that state-legal medical cannabis use remains no excuse for a positive drug test for safety-sensitive workers, as detailed by Marijuana Moment.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Hemp Gazette does not provide medical recommendations, diagnoses, or treatment plans. Always consult a qualified healthcare practitioner before making any decisions regarding your health or any medical condition. Statements concerning the therapeutic uses of hemp, cannabis, or cannabinoid-derived products have not been evaluated by Australia’s Therapeutic Goods Administration (TGA). Medicinal cannabis products in Australia are accessed via prescription pathways under TGA regulation.
